EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER

Liver Cancer Summit 2023

 

20-22 April, Estoril
Close
N. Poster
Poster title
Applicant name
Status
  1-P08 Lower risks of sodium glucose cotransporter 2 (SGLT2) inhibitors compared to dipeptidyl peptidase-4 (DPP4) inhibitors for hepatocellular carcinoma in type 2 diabetes mellitus: A population-based study Huang Helen Received Received
  1-P11 Tumour associated endothelial expression of B7-H3 predicts survival in hepatocellular carcinomas Su Jong Yu Received Received
  1-P10 CT texture analysis may predict genetic profile of mass-forming intrahepatic cholangiocarcinoma Lorenza Rimassa Received Received
  1-P06 A Notch-ligand producing niche drives the transition of pre-malignant biliary disease into cholangiocarcinoma Anabel Martinez Lyons Received Received
  1-P09 Implication of patients experience in the liver cancer multidisciplinary approach Gemma Iserte Received Received
  1-P07 Efficacy of atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: efficacy results from the interim analysis of the Phase IIIb Italian AMETHISTA trial Lorenza Rimassa Received Received
  1-P05 Macrotrabecular-Massive pattern is associated with aggressive factors, but it is not an independent predictor of tumor recurrence and overall survival in patients with hepatocellular carcinoma treated with liver resection. Alejandro Forner Received Received
  1-P01 Atezolizumab in combination with bevacizumab in patients with unresectable hepatocellular carcinoma not previously treated with systemic therapy: safety results from the interim analysis of the phase IIIb Italian AMETHISTA trial Fabio Piscaglia Received Received
  1-P04 Liquid biopsy protein biomarkers of cholangiocarcinoma risk, early diagnosis and survival mirroring tumor cells Ainhoa Lapitz Received Received
  1-P03 Myeloid cell-derived HMGB1 protects from the development of hepatocellular carcinoma Natalia Nieto Received Received
  1-P02 A novel hepatitis B virus genome integration hotspot in DEPDC5 intron-10 predicts unfavourable prognosis for hepatocellular carcinoma patients Chau-Ting Yeh Received Received
  2-P03 MAP17 promotes an epithelial-mesenchymal-amoeboid transition in hepatocellular carcinoma by switching one-carbon metabolism Claudia Gil-Pitarch Received Received
  2-P05 Feasibility of systemic anti-cancer therapy as an alternative to best supportive care in patients with advanced HCC and Child-Pugh B liver dysfunction Claudia Fulgenzi Received Received
  2-P08 Transarterial chemoembolization and systemic treatment in patients with autoimmune liver disease-associated hepatocellular carcinoma: Outcome and safety profile Louisa Stern Received Received
  2-P11 GALAD score outperforms aMAP and ALBI scores in the 5- and 10-year prediction ofhepatocellular carcinoma (HCC) development in patients with compensated advanced chronicliver disease (cACLD): a 12-year prospective study. Valentina Baldaccini Received Received
  2-P09 KLF5 upregulation is a common event in cholangiocarcinoma, acting as an oncogene and constituting a bad prognostic factor Pedro Miguel Rodrigues Received Received
  2-P04 Real World Data for Atezolizumab plus Bevacizumab in unresectable Hepatocellular Carcinoma: how does the adherence to the IMbrave150 trial inclusion criteria impact prognosis? Margherita Rimini Received Received
  2-P07 Role of SerpinB3-PD polymorphism in the prognosis of hepatocellular carcinoma Pietro Guerra Received Received
  2-P01 Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice: Final analysis of the prospective, observational REFINE study in the sorafenib-intolerant patient subgroup Elena Dimitriou Received Received
  2-P06 Safety and feasibility of Atezolizumab and Bevacizumab downstaging to liver transplantation of intermediate-advanced HCC: preliminary European experience on 7 patients Sherrie Bhoori Received Received
  2-P02 Mining the dark proteome to identify novel biomarkers in hepatocellular carcinoma Doan Duy Hai Tran Received Received
  3-P06 Immunotherapy resistance in NASH-HCC is driven by the dysfunctional liver microenvironment of NASH Daniel Geh Received Received
  3-P08 Effect of Zinc Acexamate treatment in hepatocellular carcinoma in vitro and in vivo models Monica Higuera Received Received
  3-P04 Exportin-1 (XPO-1) as a novel target for natural killer cells in hepatocellular carcinoma Salim Khakoo Received Received
  3-P09 Comparison between Regular Additional Endobiliary Radiofrequency Ablation and Photodynamic Therapy in Patients with Advanced Extrahepatic Cholangiocarcinoma under Systemic Chemotherapy Christian Möhring Received Received
  3-P03 Targeting the E2F/MCM axis in cholangiocarcinoma halts disease progression in experimental models by rewiring lipid metabolism Mikel Ruiz de Gauna Received Received
  3-P07 Identification of hepatocyte-restricted antigens, epitopes, and T cell receptors to treat recurrent hepatocellular carcinoma after liver transplantation Yannick Rakké Received Received
  3-P10 Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments Mara Persano Received Received
  3-P11 Incidence and risk factors of esophagogastric varices bleeding in patients with advanced Hepatocellular Carcinoma treated with Lenvatinib Eleonora Alimenti Received Received
  3-P05 Interplay between genetic and immune factors in the tumor microenvironment and their prognostic value in hepatocellular carcinoma. Filip Ambrozkiewicz Received Received
  3-P02 Management of varices but not anticoagulation is associated with improved outcome in patients with hepatocellular carcinoma and macrovascular tumour invasion Lorenz Balcar Received Received
  3-P01 Glypican-3 targeted radiopharmaceutical therapy for hepatocellular carcinoma: Preclinical characterization of a novel peptide binder Gary Li Received Received
  4-P11 Time-trends in cholangiocarcinoma incidence - a Danish nationwide cohort study Morten Daniel Jensen Received Received
  4-P04 Artificial intelligence and deep learning models used for the classification and navigation of liver ultrasound protocols for patients with hepatocellular carcinoma Joseph Klepich Received Received
  4-P01 Barriers to hepatocellular carcinoma screening at a single Veterans Affairs center: a quality improvement initiative Maureen Onweni-Eze Received Received
  4-P03 The ALBI grade refines prognostic prediction in advanced hepatocellular cancer and enables risk stratification for bleeding events following atezolizumab plus bevacizumab. Antonio DAlessio Received Received
  4-P02 Value based Healthcare: Patient perception of the liver cancer Advanced Practice Nurse care at the Barcelona Clinic Liver Cancer Neus Llarch Received Received
  4-P06 Peripheral immune markers can detect hepatocellular carcinoma in blood in a Latin American cohort Boonstra Andre Received Received
  4-P05 Cryptogenic non-cirrhotic HCC: clinical, prognostic and immunologic aspects of an emerging HCC etiology Boonstra Andre Received Received
  4-P09 Dissecting the tumor heterogeneity and tumor microenvironment in intrahepatic cholangiocarcinoma using spatial transcriptomics Mareike Polenkowski Received Received
  4-P10 An innovative human-derived Cholangiocarcinoma-on-chip as a platform for targeted therapy Michela Anna Polidoro Received Received
  4-P08 The role of Aurora kinase A in hepatocellular carcinoma: possible regulation of Programmed death-ligand 1 Luca Grisetti Received Received
  4-P07 Fibroblast growth factor 21 delays hepatocellular carcinoma development and is critical for liver regeneration in a murine model of moderate and severe liver injury Hanna Luisa Martin Received Received
  5-P01 Predicting cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib Bernardo Stefanini Received Received
  5-P11 Therapeutic potential of targeting protein hyper-SUMOylation in cholangiocarcinoma Paula Olaizola Rebe Received Received
  5-P07 The earliest integration of hepatitis B virus into hepatocyte genome: sites, mechanism and role in HCC oncogenesis Thomas I. Michalak Received Received
  5-P10 Targeting epigenetics in preclinical models of Hepatocellular Carcinoma for translational therapy. Anastasia Georgakopoulou Received Received
  5-P08 A novel hepatocellular cancer patient derived organoid xenograft model to investigate impact of liver regeneration on tumor growth Fabian Haak Received Received
  5-P03 Centrosome amplification is attributed to glutamine metabolism in the developments of liver fibrosis and liver tumors Caroline Oi-Ling Yu Received Received
  5-P06 Impact of the covid-19 pandemic on the treatment of resectable liver neoplasias: a cross-sectional study from Brazil Laynara Vitória Da Silva Vieira Received Received
  5-P05 ASSOCIATION OF TP53 WITH DEFECTIVE LONG CHAIN 3-HYDROXY ACYL-CoA DEHYDROGENASE INDUCED NON-CIRRHOTIC HEPATOCELLULAR CARCINOMA Tripti Khare Received Received
  5-P09 Prognostic impact of metastatic site in patients receiving first-line sorafenib therapy for advanced hepatocellular carcinoma Luca Ielasi Received Received
  6-P05 Preferential effects of PARP-1 inhibition in KRAS-mutated intrahepatic cholangiocarcinoma is mediated by CHK1 kinase Darko Castven Received Received
  6-P06 Gamma-aminobutyric acid B2 receptor as a potential therapeutic target for cholangiocarcinoma with diabetes mellitus Charupong Saengboonmee Received Received
  6-P02 Novel platinum-based chemotherapeutic agents halt cholangiocarcinoma progression through the induction of inter-strand DNA breaks, preventing DNA repair mechanisms Irene Olaizola Rebe Received Received
  6-P07 KDM2A histone demethylase ablation restores immunogenicity in liver cancer Elisa Morganti Received Received
  6-P03 Proteomic profile matching predicts treatment response in advanced hepatocellular carcinoma for precision medecine Frederic SALTEL Received Received
  6-P10 Metabolic rewiring by increased mitochondrial respiration drives immunosuppression in liver cancer Naroa Goikoetxea Usandizaga Received Received
  6-P01 Survival outcomes from Atezolizumab plus Bevacizumab versus Lenvatinib versus Sorafenib in Child Pugh B unresectable hepatocellular carcinoma patients. Margherita Rimini Received Received
  6-P08 A prognostic nomogram of CDKs/CDKLs-related genes for hepatocellular carcinoma Ningning Zhang Received Received
  6-P04 Scavenger receptor MARCO is associated with an immunosuppressive microenvironment and tumor progression in intrahepatic cholangiocarcinoma Aloña Agirre Lizaso Received Received
  7-P02 Modelling hepatocellular carcinoma in precision-cut liver slices for therapeutic screening and as a precision medicine tool Amy Collins Received Received
  7-P03 Identification and experimental validation of druggable epigenetic targets in hepatoblastoma. Claveria-Cabello Alex Received Received
  7-P10 T cell and myeloid cell interactions differ in tumour and non-tumour regions in hepatocellular carcinoma Cositha Santhakumar Received Received
  7-P08 Baveno VI and VII criteria are not suitable for screening of large size esophageal varices and clinically significant portal hypertension in patients with HCC Manon Allaire Received Received
  7-P07 Metformin and statin reduce the risk of hepatocellular carcinoma among chronic hepatitis C patients failed to antiviral therapy Pei-Chien Tsai Received Received
  7-P06 Pediatric liver cancer: Hepatoblastoma and Neddylation post-translational modification Leidy Estefanía Zapata-Pavas Received Received
  7-P05 Developing image-guided precision radiotherapy in preclinical liver cancer models Stephanie May Received Received
  7-P09 Trial in progress: An open-label, multicenter study investigating RP3 oncolytic immunotherapy in combination with first- or second-line systemic atezolizumab and bevacizumab in locally advanced unresectable or metastatic hepatocellular carcinoma Jane Kovalevich Received Received
  7-P11 miRNome profiling analysis reveals novel hepatocellular carcinoma diagnostic, prognostic and treatment-related candidate biomarkers: post-hoc analysis of SORAMIC trail Egidijus Morkunas Received Received
  7-P04 Portal-hypertension parameters are associated with survival and ascites occurrence in patients with hepatocellular carcinoma treated by external radiotherapy Héloïse Giudicelli Received Received
  7-P01 Silencing CNNM4 in cholangiocarcinoma inhibits tumoral progression by means of non-canonical ferroptosis Maria Mercado-Gómez Received Received
  8-P03 Spheroids derived from aggressive hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (iCCA) share similar behaviour after proangiogenic stimulation Adriana Romanzi Received Received
  8-P11 secondary surveillance following curative treatment of hepatocellular carcinoma: a systematic review Shauntelle Quammie Received Received
  8-P01 MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma Ilaria Leoni Received Received
  8-P09 Oncogenic role of the Hepatitis B Virus surface antigen during hepatocarcinogenesis Agustiningsih Agustiningsih Received Received
  8-P08 Impact of sarcopenia on survival of patients with hepatocellular carcinoma treated with sorafenib Lorenzo Lani Received Received
  8-P07 The Differences in Profiles of Intratumoral Microbiota in Cholangiocarcinoma and Hepatocellular Carcinoma are Observed Thanika Ketpueak Received Received
  8-P06 Clinical and biologic qualification of the ABRS gene signature, a putative biomarker of benefit to atezolizumab and bevacizumab in advanced hepatocellular cancer Cian Murphy Received Received
  8-P04 Incidence rates, trends, and survival for etiology-specific hepatocellular carcinoma and cholangiocarcinoma in the Unites States. Paulo Pinheiro Received Received
  8-P05 Cytokine levels and circulating DNA profiling in plasma as biomarkers of response to immunotherapy in hepatocellular carcinoma Elena Vargas Accarino Received Received
  8-P02 Phenotypic characteristics of primary cholangiocarcinoma in a large French cohort of patients with viral chronic liver disease followed-up before and after viral eradication: an ANRS study Alina Pascale Received Received
  8-P10 Collagen proportionate area (CPA) measurement of liver parenchyma and hepatocellular carcinoma (HCC) can predict HCC recurrence after liver resection Federico Ravaioli Received Received
  9-P10 Uncovering epigenetic essentialities of intrahepatic cholangiocarcinoma Juan Lafuente-Barquero Received Received
  9-P07 Hepatocellular Carcinoma in HIV-infected patients: clinical presentation and outcomes Eleonora Alimenti Received Received
  9-P06 Correlation of single nucleotide polymorphisms and hepatocellular carcinoma in a Latin American population Boonstra Andre Received Received
  9-P08 Stabilization of O-GlcNAcylation increases Enhancer of Zeste Homolog 2 (Ezh2) direct targets in hepatocellular carcinoma Margot Thirion Received Received
  9-P02 chimeric antigen receptor-engineered memory-like natural killer cells: a novel therapy for hepatocellular carcinoma Rosalba Biondo Received Received
  9-P11 Landmark analysis of the risk of recurrence after resection or ablation for hepatocellular carcinoma: a nationwide study Frederik Kraglund Received Received
  9-P01 Developing new therapies for primary liver cancer with precision bio-printed patient-derived organoids Benjamin Dwyer Received Received
  9-P09 Impact of PNPLA3 rs738409 polymorphism on the development of hepatocellular carcinoma in female patients with non-alcoholic fatty liver disease and severe liver fibrosis Nuria Pérez Diaz del Campo Received Received
  9-P05 Evaluation of ESPL1 level in peripheral blood of patients with HBV infection for early warning of HCC occurrence and recurrence Hengkai Liang Received Received
  10-P04 Predictive performance of HCC risk scores in chronic hepatitis C patients with advanced fibrosis after achieving SVR: Real-world experience from a tertiary UK centre Riham Soliman Received Received
  10-P10 Adverse events related to atezolizumab-bevacizumab is comparable among CTP-A and B and more safer than TKIs for Hepatocellular carcinoma Anand Kulkarni Received Received
  10-P05 Correction for length bias reduces the mortality benefit from Hepatocellular Carcinoma surveillance Callum Robins Received Received
  10-P09 Novel approaches to improve immunotherapy for NASH-induced HCC Chaofan Fan Received Received
  10-P06 Role of Etiology in Hepatocellular Carcinoma Patients Treated with Lenvatinib: A Counterfactual Event-Based Mediation Analysis Rodolfo Sacco Received Received
  10-P11 identifying and analyzing metabolic reprogramming in hcc. Asha Balakrishnan Received Received
  10-P02 miR-21-5p promotes NASH-related hepatocarcinogenesis André L. Simão Received Received
  10-P01 The tumor milieu of Intrahepatic Cholangiocarcinoma: dissecting the phenotypical and molecular properties of B lymphocytes in affected patients Giulia Milardi Received Received
  10-P07 Hepatocellular carcinoma (HCC) management in a tertiary HPB centre - lessons from the southeast coast of the UK Darren DSouza Received Received
  10-P03 RIPK3 impacts tumor burden and liver immunophenotype in toxic/dietary models of hepatocellular carcinoma André Cardador Received Received
  11-P02 The importance of contrast enhanced ultrasonography and elastography as predictors for hepatocellular carcinoma recurrence following treatment with percutaneous microwave ablation or transarterial chemoembolization Razvan Rababoc Received Received
  11-P07 Regorafenib in patients with unresectable hepatocellular carcinoma in real-world practice in the European Union: Final analysis of the prospective, observational REFINE study Elena Dimitriou Received Received
  11-P06 Prognostic performance of Toronto HCC risk index and the alpha-fetoprotein rate in patients with Hepatocellular carcinoma Nouha Trad Received Received
  11-P01 Tolerability of first line systemic therapy in elderly patients with advanced hepatocellular carcinoma Giulia Francesca Manfredi Received Received
  11-P10 Alpha-Fetoprotein Response Patterns after Y-90 Radioembolization for Intermediate-to-Advanced Hepatocellular Carcinoma Predict Disease Progression and Survival Justin Tse Received Received
  11-P05 The epidemiology of hepatocellular carcinoma has changed in our region ... But, what has really changed ? Edeline Kaze Received Received
  11-P08 A transcriptomic signature of Intrahepatic Cholangiocellular Carcinoma with very early recurrence: Identifying patients at risk Fabian Haak Received Received
  11-P09 Atezolizumab/Bevacizumab combination therapy seems to benefit mainly BCLC-C cirrhotic patients with hepatocellular carcinoma who migrate to this stage after disease recurrence following resection or radiofrequency ablation Spyridon Pantzios Received Received
  11-P04 Hypofractionated Carbon Ion Radiation in patients with primary liver cancer Paula Hoffmeister-Wittmann Received Received
  11-P03 Robotic and laparoscopic surgery versus open surgery for perihilar cholangiocarcinoma: systematic review and meta-analysis Laynara Vitória Da Silva Vieira Received Received
  12-P07 Survival in people living with HIV with or without recurrence of hepatocellular carcinoma after invasive therapy Costanza Bertoni Received Received
  12-P09 The role of thyroid hormone signalling in liver carcinogenesis: a proof of knowledge Valentina Cossiga Received Received
  12-P01 Evaluation of hepatocellular carcinoma and mortality in Budd-Chiari syndrome Zülal Istemihan Received Received
  12-P02 Updated survival outcomes with ivosidenib in patients with previously treated IDH1-mutated intrahepatic-cholangiocarcinoma: an Italian real-world experience. Margherita Rimini Received Received
  12-P05 ??????????? ???? ??????????????? ??????????? ????????????????? ????????? Alexander Fedusenko Received Received
  12-P10 Expression of MIR-199-5p in chronic viral hepatitis and hepatocellular carcinoma Elizaveta Joldasova Received Received
  12-P03 Use of cytokine TGF 1 in DETECTION of Hepatocellular carcinoma in patients with chronic liver disease Amila Mehmedovic Received Received
  12-P04 The potential of combined treatments between Src tyrosine kinase inhibitors and sorafenib in heterogeneous liver cancer cells Loraine Kay Cabral Received Received
  12-P08 Temporal trends in Hepatocellular carcinoma in Pakistan Aimun Raees Received Received
  12-P06 The association of glucagon-like peptide-1 receptor and poor prognosis of Northeastern Thai patients with cholangiocarcinoma Ronnakrit Trakoonsenathong Received Received
  12-P11 Reduced expression of YAP is associated with transition of pre-invasive to invasive state in an organoid-derived model of cholangiocarcinoma Fatima Manzano-Nuñez Received Received
  13-P05 Inhibiting methionine aminopeptidase 2 suppressed VEGFA-mediated angiogenesis by enhancing phosphorylation of eIF2a Yongtao Wang Received Received
  13-P08 The gene expressions and bioinformatics analysis of miR-146b-5p and miR-4510 in Hepatocellular Carcinoma Duygu BIRCAN KADIOGLU Received Received
  13-P10 Poor sorafenib response in hepatocellular carcinoma is mediated by hypoxia-related 14-3-3 scaffolding proteins and induces shift in immune micromilieu Jovana Castven Received Received
  13-P02 Glycosylated 4-methylumbelliferone reduces the expressions of cancer stem cells in hepatocellular carcinoma Caecilia Sukowati Received Received
  13-P09 TARDBP Is a Prognostic Biomarker and Correlates With Immune Infiltrates in Liver hepatocellular carcinoma Ningning Zhang Received Received
  13-P04 Investigation of novel hepatoblastoma chemosensitizers based on the inhibition of ABC pumps-mediated drug efflux Rocio IR Macias Received Received
  13-P06 Synergistic Anticancer Effect of Immunotherapy and PI3K? Inhibition Combination Therapy in Liver Cancer Sue Hyuck Received Received
  13-P01 PRAME is a target of Gas6/Axl signaling in hepatocellular carcinoma Wolfgang Mikulits Received Received
  13-P07 It takes a team for HCC: improvement of outcome with the multidisciplinary ambulatory for systemic therapy Dalbeni Andrea Received Received
  13-P03 Therapeutic potential of engineered oncolytic virus 3020-VV13 in a pre-clinical model of hepatocellular carcinoma Hyeree Kim Received Received
  14-P06 The role of radiomics in the diagnostic and therapeutic path of hepatocellular carcinoma treated with trans arterial radio embolization Flavia Federici Received Received
  14-P05 The role of radiomics in diagnosis and therapeutic path of hepatocellular carcinoma treated with transarterial chemoembolization Paola Ferrari Received Received
  14-P10 Oncostatin M promotes a pro-tumorigenic inflammatory response in NASH-related HCC Beatrice Foglia Received Received
  14-P01 Validation of the CRAFITY score in patients with hepatocellular carcinoma treated with atezolizumab and bevacizumab Bernhard Scheiner Received Received
  14-P09 Effects of Rifaximin on Epigenetic and Autophagy Markers in an Experimental Model of Hepatocellular Carcinoma Secondary to Non-alcoholic Fatty Liver Disease. Matheus Michalczuk Received Received
  14-P02 Cellular interrogation of changes to anti-tumour immunity in Hepatocellular Carcinoma following treatment with combined atezolizumab and bevacizumab using human Precision-Cut Tumour Slices Ravi Jagatia Received Received
  14-P11 Carcinogenesis risk factors in cirrhotic patients with dysplastic nodules Elena Laura Iliescu Received Received
  14-P07 Hepatocellular Carcinoma cell lines growth inhibition by liver-derived mensenchymal stem cells in direct 3D co-culture Grégory de Bodt Received Received
  14-P03 Clinical characteristics, treatments and outcomes in patients diagnosed with hepatocellular carcinoma (HCC) receiving locoregional treatment in England Sophia Le Mare Received Received
  15-P08 Tolerance and efficacy of the early switch towards atezolizumab bevacizumab after failure of ive internal radiation therapy for hepatocellular carcinoma Yasmina Ben Merabet Received Received
  15-P01 Inhibiting endoplasmic reticulum stress enhances the effect of doxorubicin by affecting lipid metabolism in hepatocellular carcinoma MARIA KOPSIDA Received Received
  15-P06 Fascin-1 as a druggable target in agressive hepatoblastoma Lydia DIF Received Received
  15-P10 Long-term survival in patients with unresectable liver cancer treated with lenvatinib Maria Teresa Ferrer Rios Received Received
  15-P02 Interim analysis of the ACTION trial: Cabozantinib for hepatocellular carcinoma patients who discontinued first line treatment different to sorafenib or due to sorafenib intolerance Marco Sanduzzi Zamparelli Received Received
  15-P05 Hepatocellular carcinoma incidence and risk stratification in patients with non-alcoholic fatty liver disease on long-term follow-up Marta Guariglia Received Received
  15-P07 NMS-01940153E, an MPS1 inhibitor with anti-tumor activity in relapsed or refractory unresectable hepatocellular carcinoma Domenico Roberti Received Received
  15-P11 A prospective study for validation of General Evaluation Score for hepatocellular carcinoma risk stratification in chronic hepatitis C patients Gamal Shiha Received Received
  16-P11 Influence of the SUSTAINED VIRAL RESPONSE (SVR) in patients with cirrhosis due to HEPATITIS C VIRUS (HCV) and diagnosis of HEPATOCELLULAR CARCINOMA (HCC) Maria Varela Received Received
  16-P04 Serum HCC biomarkers AFP, PIVKAII and GPC-3 correlate differently with the HCC characteristics and clinic-pathologic features. Francesco Damone Received Received
  16-P07 Establishment and characterization of a patient derived xenograft model of cholangiocarcinoma Denise Schlösser Received Received
  16-P06 Glycogen as metabolic fuel for tumor development in glycogen storage disease type III Valle Montalvo Romeral Received Received
  16-P05 Prognostic role of thyroid volume reduction in patients treated with lenvatinib for advanced hepatocellular carcinoma Luca Ielasi Received Received
  16-P08 INTERLEUKIN-6: a new marker of advanced-sarcopenic HCC cirrhotic patients Leonardo Antonio Natola Received Received
  16-P01 Validation of serum biomarker panels for early HCC detection: Results from a large prospective Latin American multicenter study Boonstra Andre Received Received
  16-P09 Liposomal doxorubicin targeted with atezolizumab as a novel strategy to cure HCC: preclinical in vitro and in vivo studies Sara De Martin Received Received
  17-P10 Peritumoral portal enhancement during transarterial chemoembolization a potential prognostic factor for patients with hepatocellular carcinoma Sofi Sennefelt Nyman Received Received
  17-P06 Fatty acid synthase promotes the malignant features of cholangiocarcinoma cells and predicts survival in patients Giulia Lori Received Received
  17-P05 Liver function is a predictor of survival in patients with hepatocellular carcinoma in best supportive care Fabio Marra Received Received
  17-P01 Poor compliance in the surveillance for Hepatocellular carcinoma (HCC) in a real world setting. Maria Melanie Deutsch Received Received
  17-P07 Rising admissions and treatments for hepatocellular carcinoma in Irish hospitals (2009-2020) William Shanahan Received Received
  17-P03 Mangiferin & Resveratrol; novel nutraceuticals regulating CD8 cell cytotoxicity and pivotal immunoregulatory pathways in hepatocellular carcinoma Yousra Eldiwany Received Received
  17-P09 Insulin-like growth factor-binding proteins 2 and 3 and the occurrence, characteristics, and outcome of hepatitis C-related hepatocellular carcinoma: A case-control study hend ibrahim shousha Received Received
  17-P04 Multidisciplinary approach to Hepatocellular Carcinoma management in a low-income country Aimun Raees Received Received
  17-P08 Impact of surveillance strategies for hepatocellular carcinoma on patients with chronic liver diseases Timofte Oana Received Received
  17-P02 Cystic Fibrosis may be an exclusion criteria for LI-RADS Chuhadry Khuram Shahzad Received Received
  17-P11 Inflammation and immune-based prognostic scores as prognostic biomarkers for HCC treatment: A single-center study in the last decade Merve Guzel Dirim Received Received
  18-P06 Predictors of extrahepatic recurrence after transarterial chemoembolization as first-line therapy for hepatocellular carcinoma Elisa Pinto Received Received
  18-P09 Immune checkpoint inhibitor treatment has the potential to stabilize liver function in patients with hepatocellular carcinoma Katharina Pomej Received Received
  18-P02 Influence of hepatocellular carcinoma surveillance programs on cirrhotic patients survival: A real life study Félix Fernández García Received Received
  18-P03 Early diagnosis of hepatocellular carcinoma at the level of an infectious diseases hospital Krestina Brigida Received Received
  18-P04 Serum protein glycomics in treatment-naive HCC patients are strongly associated to two-year overall survival and HCC relapse Nicky Somers Received Received
  18-P01 Prognostic performance of Toronto HCC risk index in patients with Hepatocellular carcinoma Nouha Trad Received Received
  18-P05 What changed in hepatocellular carcinoma presentation in the last eleven years? Comparison of two sequential time series from a tertiary hospital Ana Craciun Received Received
  18-P08 Immunomonitoring of hepatocellular carcinoma patients undergoing liver transplantation after treatment with Bevacizumab and Atezolizumab Sherrie Bhoori Received Received
  18-P07 Programmable DNA hydrogel assisting microcrystal formulations for sustained locoregional drug delivery in residual tumor foci Hao Feng Received Received
  18-P10 Gender differences in patients with hepatocellular carcinoma Agata Ladic Received Received
  19-P07 Varices and thrombocytopenia are predictors of survival outcome after liver resection for hepatocellular carcinoma (HCC): a twenty-year retrospective study Samir Tariq Received Received
  19-P01 Ablation of large HCC using a new mini-invasive RFA device with 4 very thincool-tip needles Luciano Tarantino Received Received
  19-P04 Efficacy of LENVATINIB in intermediate stage and advanced HEPATOCELLULAR CARCINOMA: results of MONOTHERAPY and COMBINATION with LOCOREGIONAL TREATMENT Margherita Spigaroli Received Received
  19-P09 Comparison between hepatocellular carcinoma in alcohol related disease versus other etiologies - are they the same or not quite yet? A retrospective analysis. Jessica Chaves Received Received
  19-P08 Fib4 can help cost effective HCC screening populations in Child Pugh A cirrhosis Paul Armstrong Received Received
  19-P03 In vivo characterization of the impact of distinct p53 mutations in hepatocellular carcinoma Marine Bernardet Received Received
  19-P02 Liver transplantation for HCC beyond Milan criteria after down-staging with stereotactic radiotherapy or transarterial radioembolization Alberto Calleri Received Received
  19-P11 Epidemiology of hepatocelullar carcinoma in transylvania Elena Cristina Rezi Received Received
  20-P05 Disparities in access to timely diagnosis and treatment for hepatocellular carcinoma - need for standardisation across cancer types Niamh Mehigan Received Received
  20-P10 Assesment Of GALAD Score As Diagnostic And Prognostic Factor Of Denovo Hepatocellular Carcinoma Post Treatment With Direct Acting Antiviral Agents hend ibrahim shousha Received Received
  20-P08 TKI treatments for HCC before liver transplantation: a collaborative European study. Chiara Mazzarelli Received Received
  20-P09 PNPLA3 rs738409 CG polymorphism impact on HCV-Related HCC development in a Brazilian population: preliminary results Claudia Maccali Received Received
  20-P04 Is ALBI score alone a good predictor for outcome in patients treated with radioembolization for hepatocellular carcinoma? maria alessia papassifachis Received Received
  21-P3 Early detection of hepatocellular carcinoma via no end-repair enzymatic methylation sequencing of cell-free DNA and pre-trained neural network Yongkun Ji Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
18:13
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

Liver Cancer Summit 2023

 

20-22 April, Estoril
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 20/04/2023 TO 20/04/2024
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert